LitCovid-sample-Enju  

PMC:7253482 / 74-402 JSONTXT 20 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T8 5-13 NN denotes Abstract
T9 14-20 JJ denotes Severe
T10 21-26 JJ denotes acute
T11 27-38 JJ denotes respiratory
T12 39-47 NN denotes syndrome
T13 48-49 -LRB- denotes (
T14 49-53 NN denotes SARS
T15 53-54 -RRB- denotes )
T16 55-58 CC denotes and
T17 59-65 NNP denotes Middle
T18 66-70 NNP denotes East
T19 71-82 JJ denotes respiratory
T20 83-91 NN denotes syndrome
T21 92-93 -LRB- denotes (
T22 93-97 NNS denotes MERS
T23 97-98 -RRB- denotes )
T24 99-112 NNS denotes coronaviruses
T25 113-114 -LRB- denotes (
T26 114-118 NNS denotes CoVs
T27 118-119 -RRB- denotes )
T28 120-123 VBP denotes are
T29 124-132 JJ denotes zoonotic
T30 133-142 NNS denotes pathogens
T31 143-147 IN denotes with
T32 148-152 JJ denotes high
T33 153-161 NN denotes fatality
T34 162-167 NNS denotes rates
T35 168-171 CC denotes and
T36 172-180 JJ denotes pandemic
T37 181-190 NN denotes potential
T38 192-199 NN denotes Vaccine
T39 200-211 NN denotes development
T40 212-219 VBZ denotes focuses
T41 220-222 IN denotes on
T42 223-226 DT denotes the
T43 227-236 JJ denotes principal
T44 237-243 NN denotes target
T45 244-246 IN denotes of
T46 247-250 DT denotes the
T47 251-263 VBG denotes neutralizing
T48 264-271 JJ denotes humoral
T49 272-278 JJ denotes immune
T50 279-287 NN denotes response
T51 287-288 -COMMA- denotes ,
T52 289-292 DT denotes the
T53 293-298 NN denotes spike
T54 299-300 -LRB- denotes (
T55 300-301 NN denotes S
T56 301-302 -RRB- denotes )
T57 303-315 NN denotes glycoprotein
T58 317-328 NN denotes Coronavirus
R10 T12 T13 arg1Of syndrome,(
R11 T14 T13 arg2Of SARS,(
R12 T15 T13 arg3Of ),(
R13 T12 T16 arg1Of syndrome,and
R14 T20 T16 arg2Of syndrome,and
R15 T18 T17 arg1Of East,Middle
R16 T20 T18 arg1Of syndrome,East
R17 T20 T19 arg1Of syndrome,respiratory
R18 T20 T21 arg1Of syndrome,(
R19 T22 T21 arg2Of MERS,(
R20 T23 T21 arg3Of ),(
R21 T28 T24 arg1Of are,coronaviruses
R22 T24 T25 arg1Of coronaviruses,(
R23 T26 T25 arg2Of CoVs,(
R24 T27 T25 arg3Of ),(
R25 T16 T28 arg1Of and,are
R26 T30 T28 arg2Of pathogens,are
R27 T30 T29 arg1Of pathogens,zoonotic
R28 T30 T31 arg1Of pathogens,with
R29 T35 T31 arg2Of and,with
R30 T34 T32 arg1Of rates,high
R31 T34 T33 arg1Of rates,fatality
R32 T34 T35 arg1Of rates,and
R33 T37 T35 arg2Of potential,and
R34 T37 T36 arg1Of potential,pandemic
R35 T39 T38 arg1Of development,Vaccine
R36 T39 T40 arg1Of development,focuses
R37 T40 T41 arg1Of focuses,on
R38 T44 T41 arg2Of target,on
R39 T44 T42 arg1Of target,the
R40 T44 T43 arg1Of target,principal
R41 T44 T45 arg1Of target,of
R42 T50 T45 arg2Of response,of
R43 T50 T46 arg1Of response,the
R44 T50 T47 arg1Of response,neutralizing
R45 T50 T48 arg1Of response,humoral
R46 T50 T49 arg1Of response,immune
R47 T50 T51 arg1Of response,","
R48 T57 T51 arg2Of glycoprotein,","
R49 T57 T52 arg1Of glycoprotein,the
R50 T57 T53 arg1Of glycoprotein,spike
R51 T53 T54 arg1Of spike,(
R52 T55 T54 arg2Of S,(
R53 T56 T54 arg3Of ),(
R7 T12 T9 arg1Of syndrome,Severe
R8 T12 T10 arg1Of syndrome,acute
R9 T12 T11 arg1Of syndrome,respiratory